Tech Company Financing Transactions
Ocuphire Pharma Funding Round
Ann Arbor SPARK, Belle Capital and Biosciences Research and Commercialization Center joined a $5 million funding round for Ocuphire Pharma. The round closed on 7/23/2019.
Transaction Overview
Company Name
Announced On
7/23/2019
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds of the offering will be used to fund multiple clinical trials of its lead drug candidate, Nyxol.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
37000 Grand River Ave. 120
Farmington Hills, MI 48335
USA
Farmington Hills, MI 48335
USA
Phone
Website
Email Address
Overview
Ocuphire is a clinical-stage biopharmaceutical company engaged in the development and commercialization of drugs to treat important ophthalmic disorders. The company's lead drug candidate, preservative-free Nyxol Eye Drops, is being developed for multiple indications including night vision disturbances, glaucoma, reversal of mydriasis, and presbyopia.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mina Sooch
VP - Finance
Charlie Hoffmann
VP - Operations
Drey Coleman
VP - R & D
Konstantinos Charizanis
Browse more venture capital transactions:
Prev: 7/23/2019: UVeye venture capital transaction
Next: 7/23/2019: Homeward venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs